
Interfyl® Human Connective Tissue Matrix is an allogeneic decellularized particulate human placental connective tissue matrix.
• Available as a particulate or flowable
• 10 year shelf life
• Ambient room temperature storage
For surgical indications:
Interfyl® is intended for use as the replacement or supplementation of damaged or inadequate integumental tissue. Indications include, but are not limited to, treatment of soft tissue voids, correction of soft tissue defects, soft tissue augmentation during repair of dehisced or complicated surgical closures and repair of small surgical defects resulting from either medical or surgical conditions including those with exposed vital structures (bone, tendon, ligament, or nerve).
For wound indications:
Interfyl® is intended for use as the replacement or supplementation of damaged or inadequate integumental tissue. Indications include, but are not limited to: augmentation of deficient/inadequate soft tissue and treatment of deep dermal wounds; surgical wounds; soft tissue voids as a result of tunneling wounds, fistula tracts, or dermal undermining-including those with exposed vital structures (bone, tendon, ligament, or nerve).
If a recipient had an adverse reaction related to previous use of Interfyl, do not re-apply.
Interfyl® should not be used in clinically infected sites. Do not use Interfyl® for intravenous, intra-arterial, intra-ocular or intrathecal applications. The contents are sterile if the vial/syringe (container) is unopened and undamaged. Do not resterilize. Interfyl® must be used prior to the expiration date on the product pouch. Once opened, Interfyl® must be used within two hours or discarded per institutional procedures.
Adverse reactions or outcomes that potentially involve the use of Interfyl® must be reported promptly to the Celularity Inc. Customer Service at 1-844-963-2273.
Store Interfyl® in its original packaging in a clean, dry environment at an ambient room temperature.
Assigned HCPCS code | ● |
Minimally manipulated | |
Cryopreserved | |
Dehydrated | ● |
Desiccated | ● |
Flowable | ● |
Micronized | ● |
Sheet form | |
Requires refrigeration | |
Shelf life greater than 2 years | ● |
Shelf life limited | |
Indicated for acute wounds | ● |
Indicated for chronic wounds | ● |
Indicated for diabetic ulcers | ● |
Indicated for pressure ulcers | ● |
Indicated for surgical wounds | ● |
Indicated for third-degree burns | |
Indicated for venous ulcers | ● |
Contact manufacturer for usage guidelines |
Educational Material Available | ● |
Free Samples/Trials Available | ● |
Published Clinical Article Available | ● |
Acute Wounds
Burns
Cavity Wounds
Chronic Wounds
Deep Wounds
Dehisced Wounds
Diabetic Foot
Granulating/Epithelializing Wounds
Moderate/Highly Exudating Wounds
Non/Minimally Exudating Wounds
Palliative Wounds
Pressure Ulcers
Surgical Wounds
Superficial Wounds
Traumatic Wounds
Venous Ulcers
Aseptic technique. Apply topically. Product may be used "dry" for placement to desired area or mixed with saline or other sterile fluid for wet application. Based on physician preference and/or clinical application, the consistency can be altered by adding more or less liquid.
Celularity Inc. is a biotechnology company that produces cells and tissues derived from the postpartum placenta. Its portfolio of products supports the body's ability to regenerate tissue and includes BIOVANCE® Human Amniotic Membrane Allograft and Interfyl® Human Connective Tissue Matrix